Estrogen Therapy May Cut Alzheimer’s Risk by 35% in Women

A recent Stanford research study suggests that estrogen‑only menopausal hormone therapy could reduce Alzheimer’s disease pathology by 35% and lower the odds of developing dementia by 39% in women. The findings offer a promising avenue for women considering hormone therapy during menopause.

What the Study Reveals

The study examined the brains of women who had undergone estrogen‑only hormone therapy compared to those who had not. Researchers found a significant reduction in Alzheimer’s disease markers—such as amyloid plaques and tau tangles—in the therapy group. Additionally, statistical analysis indicated a 39% lower likelihood of dementia among women who received estrogen alone.

Why Estrogen Alone Matters

Estrogen is known to support brain health, but combined hormone therapies that include progesterone have shown mixed results. This research highlights that estrogen alone may provide neuroprotective benefits without the potential risks associated with additional hormones.

Implications for Women’s Health

These findings could influence how clinicians discuss hormone therapy options with menopausal patients. While the study offers encouraging data, it also underscores the need for personalized medical advice and further research to confirm long‑term safety and efficacy.

Next Steps for Researchers

Future studies will aim to replicate these results in larger, more diverse populations and to explore the optimal dosage and duration of estrogen therapy for cognitive protection.

Source: Fox News Health

Watch and listen free on JASTORM – Follow radio and video broadcasts free in the JASTORM app with your free account.